<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-62875</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:creator>Gómez-Ramírez, V</dc:creator>
<dc:creator>Morales-Gómez, I</dc:creator>
<dc:creator>Asensio-Sánchez, VM</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objective: To measure erythropoietin (Epo) levelsin the vitreous body from patients with proliferativediabetic retinopathy (PDR).Patients and methods: Undiluted vitreous sampleswere obtained from 44 patients who had not undergoneprior vitreous or intraocular surgery. Patientswere divided into two groups: A (n= 24) patientswith PDR and B (n= 20) patients with retinaldetachment, preretinal macular membranes andmacular holes.Epo was determined using radioimmunoassay.Results: Epo vitreous concentration in group A was512 mU/mL (range 120-880) and in group B was25.1 mU/mL (range 5.2-201) (p&lt; 0.001).Conclusions: These results show that the concentrationof Epo in the vitreous body was significantlyhigher in patients with PDR than in the controlgroup (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;83(3): 169-172, mar. 2008.</dc:source>
<dc:identifier>ibc-62875</dc:identifier>
<dc:subject>^d15223</dc:subject>
<dc:subject>^d3954^s22044</dc:subject>
<dc:subject>^d22633</dc:subject>
<dc:subject>^d15224^s29165</dc:subject>
<dc:subject>^d3954^s22009</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29387^s22002</dc:subject>
<dc:subject>^d24551</dc:subject>
<dc:type>article</dc:type>
<dc:date>200803</dc:date>
</metadata>
</record>
</ibecs-document>
